Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Handful Of Drugs Aim To Modify Osteoarthritis

Executive Summary

Disease modifying treatments in Phase II target cartilage repair and regeneration. Sponsors are enthusiastic about FDA guidance offering to help sponsors with their programs.

You may also be interested in...



Osteoarthritis Drug Development: ‘Clinically Meaningful Endpoints’ Remain Elusive

US FDA is ‘willing to look at anything’ but sponsors need to demonstrate an effect on pain as drug development challenges remain. Accompanying chart describes 32 drugs in Phase II and Phase III clinical trials and one with a pending biologics license application.

Regeneron And Teva's Fasinumab Crosses One Threshold; More Remain

The companies reported positive Phase III data testing the nerve growth factor inhibitor in patients with chronic pain, but the efficacy appears modest and safety will remain a question until long-term Phase III data read out. The companies are focused on a lower 1 mg dose.

Pfizer/Lilly's Tanezumab Reduces Osteoarthritis Pain, But Is It Safe?

Pfizer and Lilly said tanezumab reduced pain in a Phase III osteoarthritis study, but safety is the biggest question for NGF inhibitors. Yet, while Regeneron and Teva discontinued dosing for their fasinumab at its highest dose, tanezumab was effective at both doses in its first Phase III test.

Topics

Related Companies

UsernamePublicRestriction

Register

PS123780

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel